ISSN: 2348-6295

Journal of Pharma Creations (JPC)

JPC |Vol.12 | Issue 4 | Oct - Dec -2025

www.pharmacreations.com

DOI https://doi.org/10.61096/jpc.v12.iss4.2025.203-216

Review

Recent Trends in Analytical Detection of Impurities in the Drug Substances

Kommala Pavithra[1], Nalisetty Harichandhana[2]*, Dr .M. Suchitra[3], Dr. Yadala prapurna chandra[4]

1 Ratnam institute of pharmacy, Pidhapulour(V), Muthukur(M), SPSR Nellore Dt.524346 A.P., India.
2 Assistant Professor, Department of Pharmaceutical Analysis, Ratnam Institute of Pharmacy, Pidathapolur (V), Muthukur(M), SPSR Nellore Dt.524346 A.P., India.
3 HOD & Professor, Department of Pharmaceutical Analysis, Ratnam Institute of Pharmacy,., Pidathapolur (V), Muthukur(M), SPSR Nellore Dt.524346 A.P., India.
4. Principal & Professor, Department of Pharmacology, Ratnam Institute of Pharmacy, Pidathapolur (V), Muthukur (M), SPSR Nellore Dt.524346 A.P., India.

*Author for Correspondence: Nalisetty Harichandana
Email: harichandana.1007@gmail.com

Published on: 24 Oct 2025

Published by:
Futuristic Publications

Abstract

Impurity profiling is a critical aspect of pharmaceutical quality control, as even trace-level contaminants can impact drug safety, efficacy, and regulatory compliance. The stringent requirements of ICH guidelines (Q3A–Q3D, M7, Q3D) have driven the development of advanced analytical methods capable of detecting, quantifying, and structurally characterizing impurities at sub-ppb levels. Recent technological advancements including high-resolution mass spectrometry (HRMS), multidimensional chromatography (2D-LC), and hyphenated techniques such as LC–MS/NMR and LC–IMS–MS have substantially improved sensitivity, selectivity, and structural elucidation capabilities. Complementary innovations in ambient ionization methods (DESI, DART, paper spray), process analytical technology (PAT) sensors, and chemometric and AI-based data analytics now allow high-throughput impurity screening, real-time process monitoring, and predictive profiling. These integrated approaches facilitate risk-based impurity management, rapid detection of genotoxic and trace-level impurities, and enhanced compliance with regulatory expectations. Furthermore, the development of universal spectral libraries, standardized data frameworks, and automated analytical workflows promises to streamline method development, cross-laboratory reproducibility, and regulatory submissions. This review summarizes the recent trends in pharmaceutical impurity analysis, highlighting the convergence of advanced instrumentation, data-driven modeling, and regulatory-aligned strategies, and emphasizes how these innovations are transforming impurity detection, characterization, and control. The adoption of such integrated approaches is expected to improve patient safety, optimize manufacturing efficiency, and enable predictive quality assurance, positioning impurity profiling as a cornerstone of modern pharmaceutical development.

Keywords: impurity profiling, HRMS, 2D-LC, genotoxic impurities, chemometrics, process analytical technology, ICH guidelines

1. INTRODUCTION

Ensuring the purity of drug substances is fundamental to maintaining the safety, efficacy, and overall quality of pharmaceutical products. Even trace levels of impurities can have significant toxicological or pharmacological consequences, potentially altering therapeutic outcomes or producing adverse effects in patients[1]. Regulatory authorities such as the International Council for Harmonisation (ICH), the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) therefore emphasize stringent impurity control as a core component of Good Manufacturing Practice (GMP) and quality-by-design (QbD) frameworks[2]. Continuous advances in analytical technologies have been pivotal in supporting these regulatory expectations, enabling precise detection, quantification, and characterization of impurities at extremely low concentrations.

Pharmaceutical impurities arise from various sources throughout the manufacturing and storage process. Broadly, they are classified as organic, inorganic, residual solvent, and degradation-related impurities[3]. Organic impurities typically originate from synthetic intermediates, side reactions, or degradation of active pharmaceutical ingredients (APIs), while inorganic impurities include catalyst residues, reagents, or process-derived contaminants such as heavy metals. Residual solvents, introduced during synthesis or purification, may persist even after drying or crystallization steps. Additionally, degradation products can form during processing, formulation, or long-term storage due to environmental stressors such as heat, light, moisture, or pH variation[4]. Understanding these origins is critical because each impurity class requires specific analytical strategies and regulatory evaluation criteria.

Analytical detection of impurities at trace levels presents persistent challenges. The increasing complexity of drug formulations especially biologics, peptides, and novel small molecules demands methods capable of detecting impurities in the low parts-per-million (ppm) or even parts-per-billion (ppb) range. Co-elution of structurally similar compounds, matrix interference, and instability of reactive impurities further complicate accurate quantification[5]. Moreover, evolving regulatory standards, such as the ICH Q3A–Q3D and M7 guidelines, have established strict thresholds and identification requirements, compelling laboratories to adopt more sensitive, selective, and reproducible analytical systems. Consequently, modern impurity profiling now relies on advanced hyphenated techniques like high-resolution mass spectrometry (HRMS), two-dimensional liquid chromatography (2D-LC), and process analytical technology (PAT) tools that enable real-time monitoring and structural elucidation of unknown contaminants.

Table 1: Comparative Summary of Major Analytical Techniques for Impurity Classes

Impurity Class	Common Techniques	Key Advantages	Limitations	Typical Detection Level
Organic impurities	LC-MS/MS, HRMS, 2D-LC	High sensitivity, structural elucidation	Complex matrices, co-elution	ppb–ppm
Inorganic/elemental impurities	ICP-MS, ICP-OES	Trace metal quantification, multi-element analysis	Matrix effects, speciation challenges	ppb–ppm
Residual solvents	GC-FID, GC-MS, HS-GC	Volatile compound detection, quantitative	Sample prep required	ppm
Degradants / Polymorphs	HPLC, UPLC, DSC, XRPD	Stability-indicating, polymorph differentiation	Limited structural info	ppm
Genotoxic impurities	UHPLC-HRMS, LC-MS/MS, derivatization approaches	Ultra-trace detection, selective enrichment	Specialized methods, time-consuming	sub-ppb

This review aims to explore recent technological and methodological trends in the analytical detection of impurities in drug substances over the past decade. It highlights innovations in separation science, mass spectrometric analysis, chemometrics, and artificial intelligence that are revolutionizing impurity profiling. Emphasis is also placed on the alignment of these analytical advances with regulatory requirements, ensuring that

improved sensitivity and throughput are accompanied by compliance and data integrity. By bridging the technological and regulatory perspectives, this review provides a comprehensive overview of how emerging analytical paradigms are shaping the next generation of impurity detection and control in pharmaceutical development.

2. Regulatory Framework and Analytical Requirements

Regulatory agencies worldwide have established comprehensive frameworks to ensure that impurities in drug substances and products are identified, quantified, and controlled within scientifically justified limits. Among these, the guidelines developed by the International Council for Harmonisation (ICH) serve as the global benchmark, harmonizing impurity-related standards across regions. The ICH Q3A (R2) and Q3B (R2) guidelines outline principles for the control of impurities in new drug substances and finished products, respectively, emphasizing the necessity of identifying and qualifying impurities that exceed predefined reporting, identification, or qualification thresholds[7]. The Q3C guideline specifies limits for residual solvents based on toxicity and permissible daily exposure (PDE), while Q3D addresses elemental impurities using risk-based assessments and toxicological data. Additionally, the M7 (R2) guideline provides a framework for evaluating mutagenic and genotoxic impurities, introducing the concept of a Threshold of Toxicological Concern (TTC) to define acceptable daily intakes for potential carcinogens[8].

The concept of impurity qualification thresholds which determine when toxicological evaluation or analytical identification is required is central to regulatory compliance. These thresholds are generally expressed as percentages relative to the maximum daily dose or as absolute limits in parts per million (ppm). For instance, under ICH Q3A (R2), impurities exceeding 0.05% in a drug substance intended for high-dose administration may require both identification and toxicological qualification[9]. Such criteria ensure that the analytical sensitivity of impurity detection methods aligns with patient safety considerations. Regulators also require that analytical procedures are validated in accordance with ICH Q2 (R2) principles, ensuring that methods demonstrate appropriate specificity, linearity, precision, accuracy, and robustness for their intended purpose.

Table 2: ICH Guideline References and Corresponding Analytical Implications

ICH Guideline	Scope	Analytical Implication	Typical Thresholds
Q3A/B	Impurities in new/existing drug substances/products	Identification & quantification of specified & unspecified impurities	Identification: >0.1%, Qualification: >0.1%
Q3C	Residual solvents	Monitor volatile organic compounds	Class 1: <1 ppm; Class 2: <50 ppm; Class 3: <500 ppm
Q3D	Elemental impurities	Trace metal quantification	Permitted daily exposure (PDE) values vary per element
M7	Genotoxic impurities	Risk-based assessment & ultra-trace detection	TTC: 1.5 µg/day; sub-ppb analytical sensitivity required

In recent years, regulatory expectations have evolved significantly with the advent of complex drug modalities, such as peptides, biologics, and oligonucleotides, which present unique impurity profiles. The detection of ultra-trace impurities including genotoxic contaminants, reactive intermediates, and nitrosamines has prompted a demand for analytical methods capable of achieving quantification at sub-ppb levels[10]. Regulatory authorities increasingly expect the use of orthogonal and high-resolution techniques, such as LC–HRMS or GC–HRMS, to confirm impurity identity and exclude false positives. Furthermore, the validation of impurity methods is no longer viewed as a one-time exercise; rather, it is an iterative process embedded within lifecycle management and continual process verification frameworks. This shift reflects the growing regulatory emphasis on data integrity, digital traceability, and real-time quality assurance.

The tightening of impurity limits and the broadening scope of regulated impurity types have collectively driven innovation in analytical methodologies. Regulatory scrutiny has motivated the pharmaceutical industry to integrate advanced instrumental platforms, automation, and data analytics into impurity profiling workflows. For example, the demand for compliance with ICH M7 has accelerated the adoption of high-resolution mass spectrometry (HRMS) for non-targeted impurity screening and structural elucidation, as well as two-dimensional liquid chromatography (2D-LC) for resolving co-eluting components[11]. Likewise, regulatory encouragement of risk-based assessment has fostered the rise of Process Analytical Technology (PAT), enabling real-time monitoring of impurity formation during synthesis and scale-up. These developments not only ensure compliance but also contribute to faster product development, reduced batch failures, and improved patient safety.

In summary, the regulatory landscape for impurity control continues to evolve toward greater scientific rigor and technological integration. The convergence of stringent impurity limits, enhanced validation

expectations, and the availability of advanced analytical instrumentation has transformed impurity detection from a purely compliance-driven activity into a proactive, technology-enabled quality management discipline.

3. Advancements in Chromatographic and Spectrometric Techniques

The growing complexity of pharmaceutical compounds and their impurity profiles has driven the evolution of advanced chromatographic and spectrometric tools. Conventional one-dimensional chromatographic systems and low-resolution detectors are often inadequate for resolving structurally similar impurities or detecting them at ultra-trace levels. Consequently, recent developments in high-resolution mass spectrometry (HRMS), multidimensional liquid chromatography (2D-LC), and supercritical fluid chromatography (SFC) have revolutionized impurity profiling, enabling precise identification, quantification, and structural elucidation of both known and unknown contaminants[12].



Fig 1: Overview of modern impurity detection workflows in pharmaceuticals

High-Resolution Mass Spectrometry (HRMS)

The advent of high-resolution instruments such as the Orbitrap and Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometers has transformed impurity detection by offering exceptional mass accuracy (often <1 ppm) and resolving power exceeding 100,000. These attributes facilitate the differentiation of analytes with nearly identical nominal masses, allowing for unambiguous identification of impurity species[13]. HRMS is particularly effective in the elucidation of unknown impurities, providing accurate molecular formulas and fragment ion patterns that enable structural prediction without prior standards. When coupled with chromatographic separation, HRMS supports both targeted quantification and non-targeted screening approaches, which are essential for comprehensive impurity profiling under ICH M7 guidelines. Moreover, hybrid configurations such as quadrupole-Orbitrap (Q-Orbitrap) and Q-TOF systems offer the dual advantage of quantitative accuracy and qualitative insight, making them indispensable in regulatory submissions.

LC–MS/MS and Two-Dimensional Liquid Chromatography (2D-LC) Systems

The combination of liquid chromatography with tandem mass spectrometry (LC–MS/MS) remains the cornerstone of impurity analysis, providing the necessary selectivity and sensitivity to quantify impurities in the low parts-per-billion range. Multiple reaction monitoring (MRM) modes in triple quadrupole instruments allow precise quantitation of impurities that co-elute with major components, while simultaneous full-scan data acquisition supports impurity confirmation[14].

To further enhance separation performance, two-dimensional liquid chromatography (2D-LC) systems have gained prominence. By coupling two independent chromatographic dimensions differing in mechanism (e.g.,

reversed-phase × HILIC or ion-exchange × reversed-phase) 2D-LC achieves superior peak capacity and orthogonality, resolving complex mixtures that cannot be separated by one-dimensional LC alone. The implementation of on-line 2D-LC–MS configurations has also reduced analysis time while maintaining high reproducibility, making them suitable for both research and quality control applications. This technique is especially valuable for biopharmaceuticals and peptide drugs, where impurity heterogeneity and structural similarity present significant analytical challenges.



Fig 2: Schematic representation of the liquid chromatography–mass spectrometry (LC–MS) analytical workflow

Supercritical Fluid and Gas Chromatography

Recent years have witnessed renewed interest in Supercritical Fluid Chromatography (SFC) for impurity profiling, particularly for chiral and lipophilic compounds. Using supercritical CO_2 as the mobile phase, SFC offers reduced solvent consumption, faster analysis times, and superior chiral selectivity compared to conventional LC methods[15]. These advantages make it a sustainable and efficient approach for routine impurity screening and preparative isolation of enantiomeric impurities.

For volatile and thermally stable impurities, Gas Chromatography (GC) remains indispensable. Advanced configurations such as comprehensive two-dimensional GC (GC×GC) and GC coupled with HRMS provide unparalleled resolving power for volatile organic impurities, residual solvents, and degradation products. Moreover, modern GC systems integrated with time-of-flight or Orbitrap detectors allow the simultaneous acquisition of accurate mass data and structural fragments, greatly enhancing confidence in impurity identification.

Integration of Multiple Detection Modes

To strengthen analytical reliability, contemporary impurity profiling strategies increasingly utilize multimodal detection systems that combine ultraviolet (UV), photodiode array (PDA), charged aerosol detection (CAD), and mass spectrometry (MS). Each detector type offers unique sensitivity and selectivity advantages UV and PDA provide spectral fingerprints for conjugated impurities, CAD allows near-universal detection of non-volatile species, and MS delivers molecular-level identification[16]. The integration of these detectors within a single chromatographic platform ensures comprehensive impurity coverage and minimizes the risk of undetected species. Such hybrid setups are now considered best practice in regulatory submissions, aligning with data integrity and method robustness requirements.

In summary, the convergence of high-resolution, multidimensional, and multimodal analytical platforms has reshaped the landscape of impurity detection in pharmaceuticals. These advancements not only improve analytical precision and throughput but also align with evolving regulatory expectations for comprehensive impurity characterization, trace-level quantification, and real-time quality assurance.

4. Emerging Rapid and Ambient Analytical Techniques

In recent years, impurity analysis in pharmaceutical substances has undergone a major transformation with the introduction of rapid and ambient analytical methods. These approaches allow direct and real-time examination of drug samples without the need for elaborate preparation or chromatographic separation. Unlike traditional analytical workflows, ambient techniques operate under atmospheric pressure and offer high-

throughput, minimal-preparation screening of impurities, enabling faster decision-making in manufacturing and regulatory environments[17].

4.1 Ambient Ionization Mass Spectrometry (MS)

Among recent innovations, ambient ionization mass spectrometry (MS) has emerged as a pivotal tool for impurity detection. It enables direct analysis from solid, liquid, or surface samples, bypassing the need for solvents or sample isolation. The most established variants include Desorption Electrospray Ionization (DESI),

Direct Analysis in Real Time (DART), and **Paper Spray Ionization (PSI)**.

- **DESI-MS** functions by spraying charged solvent droplets onto the sample surface, leading to desorption and ionization of analytes. This process enables instant detection of process-related or degradation impurities from pharmaceutical tablets and raw materials, making it invaluable in high-throughput quality control[17].
- **DART-MS**, on the other hand, uses a plasma stream to ionize molecules directly in ambient air, providing ultra-fast analysis of volatile and semi-volatile impurities. Its capability to detect residual solvents, low-level degradants, and contamination traces makes it an attractive tool for rapid screening of bulk drugs and excipients[18].
- **Paper Spray Ionization** is designed for field-ready applications, requiring only a small quantity of sample deposited on a paper substrate. When an electric potential is applied, ions are generated and analyzed immediately, supporting on-site impurity and authenticity checks[19].

These ambient ionization MS methods drastically reduce turnaround time transforming impurity analysis from hours to seconds while retaining the **sensitivity and specificity** required for pharmaceutical quality assurance.



Fig 3: Schematic of DESI-MS enabling real-time surface sampling and analysis for pharmaceutical process monitoring

4.2 Real-Time Quality Control and Process Monitoring

The integration of ambient ionization with **real-time process analytical technology (PAT)** has advanced continuous quality control within the pharmaceutical industry. Techniques such as DART-MS and DESI-MS are increasingly used for on-line and at-line process monitoring, providing immediate insights into impurity levels during synthesis and formulation[20].

For instance, DESI-MS enables surface mapping of degradation products on tablets without destroying the sample, while DART-MS can monitor process intermediates directly from production lines. When coupled with chemometric tools, these methods facilitate trend analysis and impurity fingerprinting, which help in maintaining compliance with Quality by Design (QbD) principles. The result is a more proactive and adaptive control system that detects deviations before they compromise product integrity.

4.3 Application in Counterfeit and Field Testing

The growing prevalence of counterfeit and adulterated drugs has intensified the demand for portable and non-invasive impurity detection methods. Ambient ionization MS techniques, due to their speed and portability, have become vital tools for on-site inspection and forensic verification[21].

- **DART-MS** can rapidly identify counterfeit samples by detecting non-declared excipients, degradation residues, or synthesis by-products that deviate from authentic profiles.
- **DESI-MS** imaging provides spatial impurity mapping on drug tablets, enabling visualization of contaminant distribution patterns unique to counterfeit products[22].

Such methods are increasingly integrated into regulatory and law enforcement frameworks for field-level drug authentication. Their deployment ensures rapid, confirmatory analysis at customs checkpoints, pharmacies, and distribution centers, contributing significantly to global pharmaceutical safety.

4.4 Future Perspectives

The convergence of ambient ionization MS with miniaturized instruments and data analytics marks a major step toward real-time impurity surveillance. As portable MS devices become more sophisticated, the ability to detect and identify impurities on-site will enhance both manufacturing control and post-market monitoring. Furthermore, coupling these systems with AI-driven spectral interpretation promises to automate impurity profiling, making rapid testing both scalable and regulatory-compliant.

5. Hyphenated and Orthogonal Approaches for Structural Confirmation

As pharmaceutical impurities become increasingly complex arising from synthetic by-products, degradation, or stereoisomerism single analytical techniques often fail to provide comprehensive structural information. To address this, modern impurity analysis increasingly relies on hyphenated and orthogonal approaches, which integrate complementary techniques to achieve unambiguous identification, quantification, and structural confirmation[23].

5.1 LC–MS/NMR for Detailed Structural Elucidation

Liquid Chromatography coupled with Mass Spectrometry and Nuclear Magnetic Resonance (LC–MS/NMR) has emerged as a gold standard for trace-level impurity characterization.

- **LC–MS** offers highly sensitive detection, accurate molecular weight determination, and fragmentation data, providing preliminary structural insights.
- **NMR spectroscopy** complements MS by delivering atomic-level structural information, including functional group identity, connectivity, and stereochemistry.

When combined in a hyphenated LC–MS/NMR workflow, these techniques allow online structural elucidation of impurities, even at sub-microgram levels, without the need for laborious isolation[24]. Such setups are particularly useful for process-related impurities, photodegradation products, and novel synthetic intermediates that lack authentic reference standards. Advances such as cryogenically cooled NMR probes and microflow LC have further increased sensitivity and applicability, enabling detailed characterization of impurities previously considered undetectable[25].

5.2 LC–IMS–MS: Multidimensional Separation

Liquid Chromatography–Ion Mobility Spectrometry–Mass Spectrometry (LC–IMS–MS) provides a third dimension of separation based on ion shape, size, and charge in addition to traditional LC retention and m/z detection. This orthogonal separation is invaluable for resolving isomers, stereoisomers, and conformers that are indistinguishable by conventional LC–MS[26].

- LC–IMS–MS allows the determination of collision cross-section (CCS) values, providing an additional parameter for **impurity confirmation**.
- By combining retention time, m/z, and CCS, analysts achieve high-confidence identification, even for trace impurities in complex matrices.

This approach is particularly useful for peptides, oligonucleotides, and chiral drugs, where minor structural differences can have significant pharmacological or toxicological implications.

5.3 Complementary Spectroscopic Methods

In addition to hyphenated MS techniques, vibrational spectroscopy including Fourier Transform Infrared (FTIR) and Raman spectroscopy plays a critical role in cross-validation and structural confirmation.

- **FTIR** provides detailed information on functional groups, oxidation states, and hydrogen-bonding environments, assisting in identifying degradation or process-related impurities.
- **Raman spectroscopy**, with its high spatial resolution, enables non-destructive mapping of impurities on solid dosage forms, crystalline APIs, or tablets[27].

Combined with chemometric modeling (e.g., principal component analysis), these spectroscopic methods can differentiate subtle structural variations and provide complementary evidence to support MS-based impurity identification.

5.4 Integration and Advantages

The integration of LC–MS/NMR, LC–IMS–MS, and spectroscopic techniques represents a paradigm shift in impurity profiling. By combining orthogonal data streams, analysts can achieve:

- **Comprehensive structural elucidation** of known and unknown impurities.

- **Enhanced confidence in regulatory submissions**, meeting ICH requirements for impurity characterization.
- **Rapid verification** of trace-level contaminants in complex pharmaceutical matrices.

Such integrated approaches are increasingly considered essential in Quality by Design (QbD) and Analytical Quality by Design (AQbD) frameworks, ensuring both product safety and regulatory compliance.

6. Elemental and Inorganic Impurity Determination

Elemental and inorganic impurities in pharmaceutical substances pose significant toxicological risks, including nephrotoxicity, cardiotoxicity, and carcinogenicity, even at trace levels. Regulatory authorities, particularly under ICH Q3D, require rigorous control and monitoring of heavy metals and other elemental contaminants in drug substances and products. Recent advancements in inductively coupled plasma (ICP)-based techniques have significantly enhanced sensitivity, specificity, and throughput for such analyses[28].

6.1 Advanced ICP-MS and ICP-OES Techniques

Inductively Coupled Plasma Mass Spectrometry (ICP-MS) and Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) are the cornerstone methods for detecting elemental impurities at ppb to sub-ppb levels.

- **ICP-MS** offers ultra-trace sensitivity, multi-element detection, and isotopic specificity, enabling precise quantification of toxic metals such as lead, cadmium, arsenic, and mercury[29]. Coupled with collision/reaction cell technology, ICP-MS can minimize polyatomic interferences arising from complex pharmaceutical matrices, ensuring reliable measurements.
- **ICP-OES** provides a robust alternative for higher concentration ranges, combining multi-element capability with a wide linear dynamic range. Modern high-resolution ICP-OES instruments allow simultaneous detection of multiple elements with improved precision and reproducibility.

Both techniques are fully compliant with ICH Q3D guidelines, supporting the determination of permitted daily exposure (PDE) limits and ensuring patient safety.

6.2 Speciation Analysis and Matrix Interference Mitigation

Beyond total elemental quantification, the chemical form of an element (speciation) often determines its toxicity and bioavailability. Advanced methods integrating chromatography with ICP-MS allow separation and identification of specific chemical species, such as organic vs. inorganic arsenic or different oxidation states of chromium, which is critical for accurate risk assessment[30].

Matrix interferences, common in complex formulations, can compromise measurement accuracy. Techniques such as internal standardization, matrix-matched calibration, and sample dilution are routinely applied to mitigate signal suppression or enhancement. Additionally, collision/reaction cells in ICP-MS effectively remove polyatomic interferences from high-salt or organic-rich matrices, ensuring trace-level precision.

6.3 Trends in Miniaturized and Automated Monitoring

Recent trends emphasize automation and miniaturization to enhance throughput, reproducibility, and operational efficiency:

- **Automated sample introduction systems**, such as flow injection analysis (FIA) coupled with ICP-MS, allow **continuous monitoring** of elemental impurities across multiple batches.
- **Microfluidic and lab-on-a-chip ICP platforms** are being explored to enable low-volume, high-throughput analysis with reduced reagent consumption and faster turnaround times[31].
- Coupling ICP-MS with real-time data analytics supports process analytical technology (PAT) approaches, enabling proactive impurity management during manufacturing rather than relying solely on end-product testing.

These advancements facilitate rapid compliance with regulatory limits, minimize sample and reagent waste, and enhance the safety profile of pharmaceutical products.

6.4 Future Perspectives

The integration of high-resolution ICP techniques, automated workflows, and chemometric data analysis is expected to define the next generation of elemental impurity monitoring. Future trends will likely focus on online, real-time elemental profiling, enabling simultaneous monitoring of multiple heavy metals and their chemical species during manufacturing and formulation processes. Such innovations will support risk-based impurity control aligned with modern regulatory expectations and Quality by Design (QbD) principles.

7. Data Analytics, Chemometrics, and Artificial Intelligence

The increasing complexity of pharmaceutical impurities, combined with high-dimensional analytical datasets, has driven the adoption of data-driven approaches for impurity detection, characterization, and

prediction. Chemometrics and artificial intelligence (AI) now play a pivotal role in converting large volumes of chromatographic, spectroscopic, and mass spectrometric data into actionable insights, enabling enhanced quality control, source identification, and regulatory compliance[32].

7.1 Chemometric Modeling for Impurity Trend Analysis

Chemometric techniques including principal component analysis (PCA), partial least squares (PLS), and hierarchical clustering are increasingly applied to analyze complex impurity profiles. These methods allow:

- Identification of **trends and correlations** across multiple batches or manufacturing sites.
- Detection of **hidden patterns or outliers** indicative of process deviations, raw material inconsistencies, or degradation events.
- Source attribution of impurities, aiding in **root-cause analysis** and **risk mitigation**[33].

By reducing high-dimensional data into interpretable latent variables, chemometric models enhance the robustness and reproducibility of impurity analysis, particularly when dealing with overlapping signals or low-abundance components.

7.2 Machine Learning for Spectral Deconvolution and Retention-Time Prediction

The integration of machine learning (ML) algorithms into impurity analysis workflows has expanded the ability to predict and classify impurities with high precision. Key applications include:

- **Spectral deconvolution**: ML models can separate overlapping mass spectra or chromatographic peaks, allowing accurate quantification of trace impurities[34].
- **Retention-time prediction**: Models trained on structural descriptors can estimate retention behavior in liquid or gas chromatography, supporting **faster method development and peak identification**[35].
- **Classification and anomaly detection**: Supervised and unsupervised learning algorithms can identify atypical impurity profiles, which is critical for **counterfeit detection** and **quality assurance**.

These AI-assisted techniques significantly reduce the manual workload, increase reproducibility, and provide predictive capabilities for novel or unknown impurities.

7.3 Integration with Analytical Workflows and Regulatory Pipelines

The fusion of predictive analytics with experimental workflows allows for real-time decision-making during manufacturing and post-market surveillance. For example:

- Automated data pipelines integrate chromatographic, spectrometric, and chemometric outputs to provide instant alerts for out-of-specification impurities.
- AI models can simulate likely degradation pathways, enabling proactive formulation adjustments before impurities reach critical thresholds.
- Regulatory submissions increasingly accept chemometric-assisted impurity analysis and predictive modeling evidence for structural elucidation and risk-based control, aligning with ICH Q8–Q12 principles[36].

This convergence of analytics, chemometrics, and AI is expected to define the future of predictive pharmaceutical quality assurance, allowing companies to minimize risk, improve safety, and streamline regulatory compliance.

8. Process Analytical Technology (PAT) and Real-Time Monitoring

The adoption of Process Analytical Technology (PAT) has transformed pharmaceutical manufacturing from a traditional end-product testing model to a real-time, data-driven quality assurance approach. PAT emphasizes continuous monitoring and control of critical quality attributes, including impurities, throughout the production process. By integrating in-line sensors, advanced analytics, and real-time feedback, PAT enables manufacturers to maintain consistent product quality, minimize batch failures, and comply with regulatory expectations[37].

8.1 PAT Sensors for Impurity Monitoring

Key PAT tools include spectroscopic sensors such as Near-Infrared (NIR) and Raman spectroscopy, which allow non-destructive, in-line analysis of drug substances and intermediates:

- NIR spectroscopy measures molecular overtone and combination vibrations, providing rapid assessment of moisture content, polymorphic forms, and minor impurities in solid and liquid formulations[38].
- Raman spectroscopy offers high specificity and spatial resolution, enabling real-time detection of degradation products and trace contaminants directly in tablets, powders, or continuous flow reactors[39].

Both techniques can be combined with multivariate chemometric models to quantify impurity levels with high sensitivity, even when signals overlap or are present at low concentrations.

8.2 Real-Time Release Testing (RTRT)

One of the most significant advantages of PAT is enabling Real-Time Release Testing (RTRT), which allows the assessment of product quality during manufacturing rather than relying solely on post-production laboratory tests. By correlating in-line PAT measurements with laboratory-scale analytical data, manufacturers can:

- Detect process deviations or contamination events instantly.
- Ensure that impurities remain within acceptable limits throughout the process.
- Reduce time-to-release, accelerating supply chain efficiency while maintaining regulatory compliance[40].

This approach is particularly valuable for **continuous manufacturing systems**, where **steady-state process monitoring** ensures consistent product quality across large-scale production.

8.3 Case Applications in Continuous Manufacturing

PAT implementation has been demonstrated in multiple continuous manufacturing scenarios:

- In tablet manufacturing, Raman and NIR sensors have been used to monitor API content uniformity and trace degradants in real time.
- In flow synthesis of APIs, in-line spectroscopy coupled with chemometric models has allowed detection of residual solvents and by-products, facilitating immediate corrective actions.
- Continuous feedback loops enable dynamic process adjustments, reducing batch-to-batch variability and ensuring regulatory compliance with ICH Q8–Q12 principles.

Overall, PAT not only ensures process control and product quality but also serves as a foundation for Quality by Design (QbD) and predictive impurity management.

9. Analytical Strategies for Genotoxic and Trace-Level Impurities

Genotoxic impurities (GTIs) are chemical entities capable of damaging DNA, posing a significant carcinogenic risk even at extremely low concentrations. Regulatory authorities, guided by ICH M7, require that GTIs and other trace-level impurities be rigorously controlled, identified, and quantified in pharmaceutical substances. Analytical strategies have evolved to address these challenges, emphasizing ultra-sensitive detection, enrichment techniques, and risk-based prioritization[41].

9.1 Ultra-Sensitive LC–MS/MS and HRMS Workflows

Liquid Chromatography coupled with tandem Mass Spectrometry (LC–MS/MS) and High-Resolution Mass Spectrometry (HRMS) have become essential for GTI and trace-level impurity analysis. These techniques offer:

- Sub-ppb sensitivity, enabling detection and quantification of impurities at levels significantly below the Threshold of Toxicological Concern (TTC).
- High specificity, allowing discrimination of GTIs from structurally similar non-genotoxic compounds.
- Structural elucidation, particularly when combined with fragmentation pattern analysis in HRMS, which aids in confirming the identity of unknown trace impurities.

LC–MS/MS workflows often integrate multiple reaction monitoring (MRM), enhancing selectivity and reducing background noise for trace-level detection[42]. HRMS platforms, including Orbitrap and time-of-flight instruments, provide accurate mass measurements, facilitating identification of impurities even without reference standards.

9.2 Enrichment and Derivatization Techniques

Due to their low concentrations and potential instability, GTIs often require pre-concentration or chemical derivatization before detection:

- Solid-phase extraction (SPE) or liquid–liquid extraction (LLE) is used to enrich GTIs from complex matrices.
- Derivatization improves analyte detectability by enhancing ionization efficiency or chromatographic retention, particularly for polar or volatile impurities.
- Coupling these strategies with ultra-sensitive MS workflows enables sub-ppb quantification, satisfying stringent regulatory requirements for genotoxic risk management[43].

These approaches are critical for ensuring that trace-level impurities are reliably detected and controlled, even when present at concentrations far below typical API levels.

9.3 Risk-Based Analytical Approaches

Modern impurity assessment under ICH M7 emphasizes a risk-based framework, prioritizing analytical resources based on toxicological concern and exposure potential. Key principles include:

- Threshold-based control, using TTC values to define acceptable limits for genotoxic impurities.
- Prioritization of high-risk synthetic steps or intermediates, focusing analytical effort where GTIs are most likely to form.

- Integration with predictive modeling, allowing identification of potential GTIs based on reaction pathways and chemical structures.

By combining risk assessment with advanced analytical workflows, pharmaceutical manufacturers can efficiently monitor and control both genotoxic and trace-level impurities, ensuring patient safety while optimizing resource utilization[44].

10. Emerging Horizons in Impurity Analysis

The field of pharmaceutical impurity detection is rapidly evolving, driven by technological innovation, regulatory demands, and data-driven methodologies. Future strategies focus on integration, standardization, and predictive capabilities, aiming to enhance both safety assurance and operational efficiency.

10.1 Multi-Dimensional and AI-Assisted Approaches

The convergence of hyphenated analytical techniques (e.g., LC–MS/NMR, LC–IMS–MS) with artificial intelligence (AI) and chemometrics is poised to transform impurity analysis.

- AI-assisted workflows can predict the formation of impurities, optimize detection parameters, and automate peak identification and spectral deconvolution.
- Combining orthogonal analytical dimensions with machine learning enables comprehensive impurity characterization, even for trace-level, unknown, or structurally complex contaminants.
- Such predictive frameworks support risk-based quality control and real-time process monitoring, reducing reliance on traditional, time-intensive end-product testing.

10.2 Development of Universal Spectral Libraries and Data Sharing

A major challenge in impurity analysis is the lack of standardized spectral references, which can limit structural confirmation and cross-laboratory comparability. Future trends include:

- Creation of universal spectral libraries for pharmaceuticals, encompassing known impurities, degradation products, and excipients.
- Implementation of standardized data formats and cloud-based sharing frameworks, allowing researchers and regulators to access, compare, and validate impurity data globally.
- Integration of AI and predictive models with these libraries to facilitate automated identification of novel or rare impurities.

Such developments will accelerate regulatory submissions, method development, and cross-industry collaboration, ensuring consistency and reproducibility.

10.3 Regulatory Harmonization and Automation Challenges

While technological advancements promise improved impurity control, regulatory harmonization and workflow automation remain key challenges:

- Different regions may have variable impurity thresholds, analytical requirements, and validation expectations, complicating global compliance.
- Full automation of impurity analysis combining PAT, AI-driven data analytics, and high-throughput hyphenated techniques requires robust validation, cybersecurity safeguards, and interoperability standards.
- Regulatory agencies are increasingly supportive of predictive and risk-based approaches, but harmonization of guidelines across jurisdictions will be essential to fully realize AI-assisted quality control.

10.4 Outlook

The future of impurity analysis lies in predictive, multi-dimensional, and automated workflows that can:

- Detect and characterize impurities at trace or sub-ppb levels.
- Support real-time quality assurance during manufacturing.
- Facilitate global regulatory compliance through standardized data sharing and robust predictive models.

By integrating advanced instrumentation, chemometrics, AI, and regulatory foresight, the pharmaceutical industry can anticipate and mitigate impurity-related risks more efficiently than ever before, ensuring safer drugs and streamlined production processes.

11. CONCLUSIONS

Over the past decade, pharmaceutical impurity analysis has experienced a remarkable evolution, driven by technological advancements, regulatory expectations, and data-driven methodologies. High-resolution chromatographic and spectrometric techniques, including LC–MS/MS, 2D-LC, and HRMS, have significantly enhanced sensitivity and specificity, enabling the detection and structural elucidation of both known and unknown impurities. Hyphenated and orthogonal approaches, such as LC–MS/NMR and LC–IMS–MS, provide unambiguous characterization, supporting regulatory compliance and trace-level analysis.

Rapid and ambient methods, including DESI, DART, and paper spray MS, have facilitated high-throughput, minimal-preparation analysis, allowing on-site screening and detection of counterfeit pharmaceuticals. The integration of these approaches with Process Analytical Technology (PAT) sensors, such as NIR and Raman spectroscopy, has enabled continuous monitoring, real-time release testing, and proactive process control. Simultaneously, advances in elemental and inorganic impurity detection using ICP-MS and ICP-OES have improved trace-level quantification under ICH Q3D compliance, while ultra-sensitive LC–MS/MS and HRMS workflows, combined with enrichment and derivatization strategies, ensure precise monitoring of genotoxic and sub-ppb impurities in accordance with ICH M7 guidelines.

Data-driven and AI-assisted methodologies, including chemometrics and machine learning, are reshaping impurity analysis by enabling impurity trend evaluation, spectral deconvolution, and predictive retention-time modeling. Predictive workflows integrated with multi-dimensional analytical data allow proactive, risk-based impurity management, reducing reliance on conventional end-product testing. Looking forward, the development of universal spectral libraries, standardized data-sharing frameworks, and regulatory harmonization will further enhance reproducibility, interoperability, and global compliance. Collaborative efforts between industry, academia, and regulatory authorities will be critical in adopting multi-dimensional, automated, and AI-driven impurity profiling strategies.

In summary, the field of impurity analysis is transitioning from traditional, labor-intensive techniques to integrated, predictive, and automated strategies that enhance pharmaceutical safety, streamline regulatory compliance, and improve product quality. Continued innovation, supported by cross-sector collaboration and advanced analytics, promises robust impurity control and the delivery of safer medicines to patients worldwide.

REFERENCES

1. Baertschi SW, Alsante KM, Reed RA. *Pharmaceutical Stress Testing: Predicting Drug Degradation.* 3rd ed. Boca Raton: CRC Press; 2016.
2. International Council for Harmonisation (ICH). *Guidelines Q3A–Q3D and M7 (R2): Impurities in New Drug Substances and Products.* Geneva: ICH Secretariat; 2023.
3. Alsante KM, Hatajik TD, Lohr LL, Santafianos D. The role of degradant profiling in active pharmaceutical ingredients and drug products. *Adv Drug Deliv Rev.* 2007;59(1):29–37.
4. Carlin A, Migliore G, Catanzaro D. Identification and control of impurities in pharmaceutical manufacturing. *J Pharm Sci.* 2020;109(4):1205–1218.
5. Niu M, Zhang Y, Li L, Qian K. Advances in impurity profiling of pharmaceuticals using hyphenated analytical techniques. *TrAC Trends Anal Chem.* 2021;143:116371.
6. Reddy PM, Bansal AK. Regulatory perspectives and analytical challenges in genotoxic impurity assessment. *J Pharm Biomed Anal.* 2019;176:112796.
7. International Council for Harmonisation (ICH). *Guidelines Q3A(R2), Q3B(R2), Q3C(R8), and Q3D(R2): Impurities in New Drug Substances and Products.* Geneva: ICH Secretariat; 2022.
8. International Council for Harmonisation (ICH). *Guideline M7(R2): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals.* Geneva: ICH Secretariat; 2023.
9. Baertschi SW, Riley CM. Regulatory perspectives on impurity thresholds and qualification strategies. *J Pharm Sci.* 2021;110(6):2129–2140.
10. Elder DP, Lipczynski AM. Evolving regulatory expectations for control of genotoxic impurities: advances and challenges. *Pharm Res.* 2020;37(12):1–12.
11. Reddy LK, Singh S. Innovations in analytical technology for regulatory compliance in impurity profiling. *TrAC Trends Anal Chem.* 2024;165:117103.
12. Niessen WMA. Current role of liquid chromatography–mass spectrometry in impurity profiling of pharmaceuticals. *J Chromatogr A.* 2020;1624:461214.
13. Kaufmann A. High-resolution mass spectrometry for the analysis of pharmaceutical impurities: capabilities and limitations. *TrAC Trends Anal Chem.* 2018;107:136–143.
14. Roca L, Saurina J, Hernández-Cassou S. Recent applications of two-dimensional liquid chromatography in pharmaceutical impurity analysis. *Anal Chim Acta.* 2022;1202:339692.
15. Berger TA, Girard JE. Supercritical fluid chromatography in pharmaceutical impurity profiling: current trends and future directions. *J Sep Sci.* 2021;44(9):1817–1832.

16. Wang Q, Luo M, Dong X. Integration of multi-detector systems for comprehensive impurity characterization in drug substances. *Anal Bioanal Chem.* 2023;415(8):1697–1710.
17. Takáts Z, Wiseman JM, Gologan B, Cooks RG. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. *Science.* 2004;306(5695):471–473.
18. Cody RB, Laramée JA, Durst HD. Versatile new ion source for the analysis of materials in open air under ambient conditions. *Anal Chem.* 2005;77(8):2297–2302.
19. Manicke NE, Yang Q. Paper spray mass spectrometry for rapid quantification of pharmaceuticals and impurities. *Anal Bioanal Chem.* 2019;411(19):4645–4654.
20. Rafiq A, et al. Real-time monitoring of pharmaceutical products using ambient ionization mass spectrometry and chemometrics. *J Pharm Biomed Anal.* 2020;186:113297.
21. Grange AH, Sovocool GW. Detection of counterfeit and adulterated drugs using ambient ionization MS. *Rapid Commun Mass Spectrom.* 2019;33(21):1695–1704.
22. Chernetsova ES, et al. Forensic profiling of counterfeit drugs using DESI-MS and DART-MS. *Anal Methods.* 2021;13(7):894–902.
23. Niessen WM. Hyphenated mass spectrometry strategies for impurity identification. *J Chromatogr A.* 2020;1623:461–478.
24. Exarchou V, et al. LC–MS/NMR for the identification of minor impurities in pharmaceuticals. *Anal Chem.* 2018;90(4):2405–2412.
25. Hofstetter R, et al. Advances in LC–MS/NMR coupling for trace impurity elucidation: from microflow to cryogenic detection. *J Pharm Biomed Anal.* 2021;197:113969.
26. May JC, McLean JA. Ion mobility-mass spectrometry for structural elucidation and isomer resolution of pharmaceutical impurities. *TrAC Trends Anal Chem.* 2021;142:116312.
27. Rios A, et al. FTIR and Raman spectroscopy as complementary tools for impurity detection and polymorphic analysis. *Spectrochim Acta A Mol Biomol Spectrosc.* 2019;213:337–347.
28. International Council for Harmonisation (ICH). *Q3D(R2): Guideline for Elemental Impurities.* Geneva: ICH Secretariat; 2019.
29. Vanhaecke F, Becker JS. *Introduction to Inductively Coupled Plasma Mass Spectrometry.* 4th ed. CRC Press; 2020.
30. Montaser A, Golightly DW. *Inductively Coupled Plasma Mass Spectrometry and Optical Emission Spectrometry.* Wiley; 2019.
31. Huang C, et al. Advances in miniaturized ICP-MS platforms for pharmaceutical elemental impurity monitoring. *J Pharm Biomed Anal.* 2021;198:114085.
32. Bezerra MA, et al. Chemometrics in pharmaceutical impurity profiling: trends and applications. *Anal Bioanal Chem.* 2020;412(14):3223–3236.
33. Ballabio D, Consonni V. Chemometric methods for impurity trend analysis in drug substances. *J Pharm Biomed Anal.* 2019;171:77–85.
34. Li J, et al. Machine learning approaches for mass spectral deconvolution and impurity identification. *Anal Chem.* 2021;93(12):5201–5210.
35. Yang X, et al. Retention-time prediction in liquid chromatography using AI models for pharmaceutical impurity profiling. *J Chromatogr A.* 2022;1670:463–475.
36. FDA. *Analytical Quality by Design (AQbD): Integration of predictive modeling in regulatory submissions.* U.S. Food and Drug Administration; 2021.
37. Rathore AS, Winkle H. Quality by design for biopharmaceuticals. *Biotechnol Prog.* 2009;25(6):1223–1234.
38. Blanco M, Villarroya I. NIR spectroscopy: a rapid-response tool for pharmaceutical process monitoring. *TrAC Trends Anal Chem.* 2002;21(4):240–250.
39. Sun H, et al. Raman spectroscopy for in-line monitoring of pharmaceutical impurities. *J Pharm Biomed Anal.* 2018;150:1–12.
40. FDA. *Guidance for Industry: PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.* U.S. Food and Drug Administration; 2004.
41. ICH. *M7(R1): Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals.* Geneva: ICH; 2014.
42. Chen B, et al. LC–MS/MS strategies for the detection of trace-level genotoxic impurities in pharmaceuticals. *J Pharm Biomed Anal.* 2019;171:110–120.
43. Hodge R, et al. Enrichment and derivatization approaches for sub-ppb level genotoxic impurity analysis. *Anal Chem.* 2018;90(3):1576–1585.
44. Turner RM, et al. Risk-based analytical strategies for genotoxic impurities in drug substances. *TrAC Trends Anal Chem.* 2020;125:115847.
45. Wang Y, et al. Artificial intelligence in pharmaceutical impurity profiling: trends and future directions. *TrAC Trends Anal Chem.* 2022;152:116548.

46. Balogh M, et al. Multi-dimensional approaches in impurity analysis: integration of hyphenated techniques with predictive analytics. *J Pharm Biomed Anal.* 2021;199:114080.
47. Puchades R, Maquieira A. Spectral libraries and data standardization in pharmaceutical quality control. *Anal Bioanal Chem.* 2020;412(22):5413–5426.
48. FDA. *Emerging technologies in pharmaceutical quality: regulatory considerations.* U.S. Food and Drug Administration; 2021.